|Paul Boucher, MBA, President & CEO
Paul Boucher is the President and Chief Executive Officer of Parion Sciences and responsible for leading our senior management team and organization as we continue to advance our innovative pipeline products. Mr. Boucher joined Parion in 2006 and previously served as President as well as Vice-President of Finance and Business where he led business development, operations, finance and alliance management.Mr. Boucher has over 15 years of strategic planning, financial operations, negotiations and corporate leadership experience. Prior to joining Parion, Paul served in a corporate account leadership role at Colliers-Seely and consulted with Fortune 500 companies on their corporate real estate strategy and transaction management. Prior to Colliers-Seely, Mr. Boucher held several leadership positions at Toyota Motor Company in the areas of finance, real estate, strategic planning, and marketing. Paul also held a strategic planning role at Bristol-Myers-Squibb.Mr. Boucher holds a B.S. in Civil Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Kenan Flagler Business School. Mr. Boucher serves as a board member for the Carolina’s Chapter of the Cystic Fibrosis Foundation and as an advisory board member for the Professional Science Masters Program at the University of North Carolina, Chapel Hill. He has served as a guest lecturer at The University of North Carolina.
|Alison Church, MD
Alison Church is the Chief Medical Officer of Parion Sciences and is responsible for providing leadership and direction for Parion’s pipeline of clinical development programs. Dr. Church joined Parion in 2018 from GlaxoSmithKline where she was the Head Physician of the Dermatology Unit. Dr. Church has 9 years of experience in drug development including in the therapeutic areas of pulmonary, rare diseases, gene therapy and dermatology. During her tenure in drug development, she has led clinical teams in the global submissions and approval of Anoro© and Incruse© which are treatments for COPD. She has also led development of a gene therapy for the rare disease, metachromatic leukodystrophy, and worked on the MAA for Strimvelis, the first approved gene therapy product in the world. Dr. Church obtained her medical degree from Columbia University. She completed her pediatric residency training at Morgan Stanley Children’s Hospital of New York and her allergy/immunology fellowship training at Duke University. Dr. Church was a fellow in the Pediatric Scientist Development Program where her research project was to understand how activation of mucosal mast cells could be harnessed in the development of novel nasal vaccines for Pertussis. She maintains board certifications in both Pediatrics and Allergy/Immunology.
|Karl Donn PhD, VP Pulmonary Development
Karl Donn is currently Vice President, Respiratory R&D. He led the drug discovery program that resulted in the selection of P-1037 as a potent and durable epithelial sodium channel blocker for inhaled delivery to patients with cystic fibrosis, COPD and other respiratory diseases. He continues to lead the development of P-1037 through clinical trials. He also leads tPAD clinical development and led a variety of discovery and early development programs for at Parion. Karl has over 30 years of drug development experience in both small and large pharmaceutical companies. Prior to joining Parion, he was the VP, Global Project & Portfolio Management at GlaxoSmithKline where he developed and implemented an industry-leading R&D-wide project management organization that spanned all therapeutic areas at all R&D centers. He led several project teams, including Cialis®, Zomig® and Avodart®. Prior to his project leadership roles, Karl created and led the Clinical Pharmacokinetics / Pharmacodynamics department and provided PK/PD expertise to several projects including Zantac®, Ceftin®, Imitrex®, Ultiva®, Epivir®, Wellbutrin®, and Cerebyx®.Karl earned a BS in Pharmacy from SUNY at Buffalo, and a MS and PhD from UNC-Chapel Hill School of Pharmacy. He completed a residency in clinical pharmacy at Moses Cone Hospital and a Fellowship in Clinical Drug Research at Burroughs Wellcome Company. He serves on the National Industry Advisory Council for the State University of New York at Buffalo and was recognized by UNC-Chapel Hill School of Pharmacy with their distinguished alumnus award.
|Brian Bray PhD, VP of Chemistry, Manufacturing and Control (CMC)
Brian Bray has over 25 years of experience in the development side of the pharmaceutical industry. He joined Parion in 2015 as VP of CMC and will be responsible for drug substance, drug product and the associated regulatory documentation required to bring new chemical entities into and through clinical development. Dr. Bray earned a Ph.D. in synthetic organic chemistry at the University of Washington.After postdoctoral research at Syntex, he joined GSK as a process chemist where he worked on the scale up of both small molecule and peptide therapeutics. He left GSK to lead the CMC activities at Trimeris to progress a 36 amino acid antiretroviral peptide, T-20, from early phase 1 clinical development through an NDA and commercialization as Fuzeon(r). For this work he received the ACS Southeastern Regional Industrial Innovation Award. After Trimeris, Dr. Bray joined a small group of ex-Trimeris development scientists at Kainose Medicine to support, among others, a dry mouth program and an HIV compound. Brian was responsible for CMC and clinical development activities at Kainose. Dr. Bray served as a CMC consultant for Parion on the ENaC inhibitors P-321 and P-1037 prior to joining the company. Dr. Bray also led formulation development at BDSI prior to joining Parion.
|Anita Woodring, Vice President of Clinical & Regulatory Operations
Anita Woodring is the Vice President of Clinical and Regulatory Operations and is responsible for leading the clinical and regulatory operations for Parion’s development stage programs. Anita joined Parion in 2014 and previously served as Executive Director of Clinical and Regulatory Operations. Anita came to Parion with over 20 years of experience in pharmaceutical development at RTI International, Gilead Sciences, Inspire Pharmaceuticals and GlaxoSmithKline. During this time, Anita’s responsibilities have spanned clinical, regulatory and pharmacovigilance with a therapeutic concentration in respiratory, ophthalmic, anti-infectives and rare diseases. Anita has contributed to numerous INDs in multiple therapeutic areas as well as NDAs for 9 marketed products.Ms. Woodring holds a BS in Medical Technology from the University of Akron, an MS in Pharmaceutical Administration from University of North Carolina at Chapel Hill and a Regulatory Affairs Certification (RAC).